Abstract
Bombesin/gastrin-releasing peptide (GRP) may be involved in the growth of human breast cancers. Nude mice bearing xenografts of MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/GRP antagonists RC-3950-II and RC-3095. RC-3950-II, administered sc twice daily at a dose of 10 μg, produced significant inhibitory effects on tumor growth after 2 weeks of administration. RC-3095 acetate (D 22213), injected sc twice daily at the same dose of 10 μg, suppressed tumor growth after 4 weeks. Both RC-3950-II and RC-3095 significantly decreased the final tumor volume and tumor weights. RC-3950-I1 appeared to be somewhat more efficacious than RC-3095 in inhibiting the growth of MCF-7 MIII breast cancers. Chronic treatment with either bombesin/GRP antagonist caused down-regulation of receptors for epidermal growth factor (EGF) in tumor cell membranes, which might be related to inhibition of tumor growth. These findings suggest that bombesin/GRP antagonists should be considered for a new endocrine therapy of breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 465-472 |
Number of pages | 8 |
Journal | Biomedicine and Pharmacotherapy |
Volume | 48 |
Issue number | 10 |
DOIs | |
State | Published - 1994 |
Externally published | Yes |
Keywords
- bombesin
- breast cancer
- EGF-receptor
- GRP antagonists
ASJC Scopus subject areas
- Pharmacology